Advanced Immunotherapy Treatments

What is Immunotherapy?

Your immune system is a network of cells, tissues, and organs that protects your body from infection and disease. At the center of this defense system are white blood cells, including T cells, which can recognize and destroy abnormal cells, including some cancer cells.

Cancer cells are tricky. They often find ways to hide from the immune system or send out signals that turn immune cells “off.” Immunotherapy is a form of biological therapy designed to remove these hiding tricks, restore the immune system’s ability to recognize cancer, and boost its power to destroy diseased cells.

This is different from older cancer treatments. Chemotherapy and radiation work by directly damaging or killing cancer cells, but they can also harm healthy, fast-growing cells like hair follicles and the lining of the gut. Immunotherapy instead trains and equips the immune system itself to do the targeting, which can mean more precision for certain cancers.

Immunotherapy is not a single drug. It is a category of treatments — including checkpoint inhibitors, CAR T-cell therapy, monoclonal antibodies, cancer vaccines, cytokines, and oncolytic viruses — each working through a different biological pathway.

Immunotherapy vs. Chemotherapy vs. Radiation Therapy

Many patients receive a combination of these treatments, decided by a multidisciplinary oncology team based on cancer type, stage, and biomarker results.

Learn more about comprehensive cancer treatment in India for a full overview of available options.

How Does Immunotherapy Work?

To understand immunotherapy, it helps to understand a normal process called immune surveillance — your body’s ongoing patrol system that looks for and eliminates abnormal cells before they become a problem.

Cancer develops when abnormal cells slip past this patrol system. They do this in a few ways:

1. Disguising themselves so T cells don’t recognize them as a threat.
2. Producing checkpoint proteins, such as PD-L1, which bind to T cells and switch off their attack response.
3. Creating a hostile environment around the tumor that suppresses immune activity.

Immunotherapy interrupts this escape process. Here is a simplified, step-by-step look at how many immunotherapy drugs work:

Step 1 — Detection: Diagnostic tests identify markers on the tumor, such as PD-L1 expression or specific genetic mutations, that indicate whether immunotherapy is likely to help.

Step 2 — Blocking the “off switch”: Checkpoint inhibitor drugs block proteins like PD-1, PD-L1, or CTLA-4, which cancer cells use to deactivate T cells.

Step 3 — Reactivation: With the “off switch” blocked, T cells become active again and can recognize cancer cells as a threat.

Step 4 — Attack: Reactivated T cells multiply and attack cancer cells directly, and in some therapies, antibodies mark cancer cells for destruction by other immune cells.

Step 5 — Immune memory: In some patients, the immune system “remembers” the cancer cells, which may help control the disease over the longer term.

This process does not work the same way for every patient or every cancer type, which is why biomarker testing and specialist evaluation are essential before starting treatment.

Types of Immunotherapy

There are several major categories of cancer immunotherapy, each suited to different situations.

Checkpoint Inhibitors

Checkpoint inhibitors are drugs that block proteins such as PD-1, PD-L1, and CTLA-4, which cancer cells use to switch off T cell activity. By blocking these checkpoints, the drugs allow T cells to stay active and attack tumor cells.

• How it works: Blocks the inhibitory signal that stops T cells from attacking cancer.
• Conditions treated: Melanoma, non-small cell lung cancer, kidney cancer, bladder cancer, head and neck cancers, and certain other solid tumors.
• Benefits: Can produce long-lasting responses in some patients; available as single agents or in combination.
• Limitations: Not every patient responds; can cause immune-related side effects affecting healthy organs.

CAR T-Cell Therapy

CAR T-cell therapy is a personalized cell-based treatment. A patient’s own T cells are collected, genetically modified in a lab to recognize a specific marker on cancer cells, multiplied, and then infused back into the patient.

• How it works: Re-engineers the patient’s T cells to directly target and destroy specific cancer cells.
• Conditions treated: Currently established mainly for certain blood cancers, including specific types of leukemia, lymphoma, and multiple myeloma.
• Benefits: Can produce deep, long-lasting remissions in patients with relapsed or hard-to-treat blood cancers.
• Limitations: Requires close inpatient monitoring due to potentially serious side effects, including cytokine release syndrome and neurological effects; currently limited mostly to blood cancers, with solid tumor research ongoing.

Read about CAR T-cell therapy in detail to understand the full treatment process.

Monoclonal Antibodies

Monoclonal antibodies are lab-made proteins designed to attach to specific targets on cancer cells or immune cells.

• How it works: Can mark cancer cells for destruction, block growth signals, deliver drugs directly to tumors, or release the brakes on immune cells (as checkpoint inhibitors do).
• Conditions treated: Breast cancer, lymphoma, leukemia, colorectal cancer, and several other cancers, often used alongside chemotherapy.
• Benefits: Highly targeted; some antibodies also carry chemotherapy drugs directly to the tumor, sparing healthy tissue.
• Limitations: Effectiveness depends on the tumor expressing the specific target; infusion reactions can occur.

Cancer Vaccines

Cancer vaccines aim to trigger or strengthen an immune response against cancer-specific proteins.

• How it works: Introduces cancer-related antigens to train the immune system to recognize and attack cells carrying them.
• Conditions treated: One preventive vaccine type is used against cancers caused by certain viruses; treatment vaccines for existing cancer, such as for advanced prostate cancer, are approved in select cases, while many others remain investigational.
• Benefits: Preventive vaccines have measurably reduced rates of virus-linked cancers; treatment vaccines are a promising area of active research.
• Limitations: Most therapeutic cancer vaccines for solid tumors are still in clinical trials and are not yet standard care worldwide.

Cytokines

Cytokines are signaling proteins that help regulate immune cell activity. Certain cytokines, given at controlled doses, can boost the immune system’s overall response to cancer.

• How it works: Stimulates growth and activity of immune cells such as T cells and natural killer cells.
• Conditions treated: Historically used in advanced melanoma and kidney cancer; often now combined with newer therapies.
• Benefits: Can enhance the effect of other immunotherapies.
• Limitations: Can cause significant flu-like side effects at higher doses; largely replaced or supplemented by newer, better-tolerated therapies.

Oncolytic Virus Therapy

Oncolytic virus therapy uses modified viruses that preferentially infect and destroy cancer cells while sparing healthy tissue, and can also trigger a broader immune response against the tumor.

• How it works: The virus replicates inside cancer cells, causing them to burst, which releases tumor antigens that further alert the immune system.
• Conditions treated: One oncolytic virus therapy is approved for advanced melanoma that cannot be fully removed by surgery; research continues for other cancer types.
• Benefits: Dual action — direct cancer cell destruction plus immune activation.
• Limitations: Currently approved for a narrow set of indications; usually injected directly into accessible tumors.

Types of Immunotherapy at a Glance

Conditions Treated with Immunotherapy

Immunotherapy is an established option, often alongside other treatments, for a defined list of cancers, including:

• Lung cancer (particularly non-small cell lung cancer)
• Liver cancer (selected advanced cases)
• Melanoma (skin cancer)
• Kidney cancer (renal cell carcinoma)
• Bladder cancer
• Lymphoma (including certain Hodgkin and non-Hodgkin types)
• Leukemia (selected types, especially with CAR T-cell therapy)
• Head and neck cancers
• Breast cancer (selected patients, particularly triple-negative breast cancer)
• Colorectal cancer (selected patients with specific genetic markers)

See detailed treatment approaches for liver cancer and lung cancer.

Eligibility always depends on cancer stage, biomarker status, prior treatments, and overall health — not just the diagnosis alone.

Who Can Benefit from Immunotherapy?

Not every cancer patient is a suitable candidate for immunotherapy. Oncologists evaluate several factors before recommending it:

• Biomarker and PD-L1 testing: Tumor samples are tested for PD-L1 expression, which can help predict how well checkpoint inhibitors may work.
• Genetic and molecular testing: Certain genetic mutations or markers, such as microsatellite instability, can indicate a patient may respond well to immunotherapy.
• Cancer type and stage: Some cancers respond much better to immunotherapy than others; it may be used earlier or later in the treatment plan depending on the case.
• Overall health and organ function: Because immunotherapy affects the whole immune system, doctors assess for pre-existing autoimmune conditions or organ issues that could increase risk.
• Multidisciplinary evaluation: Oncologists, radiologists, pathologists, and sometimes immunologists review each case together to design a personalized treatment plan.

This is why a thorough consultation and diagnostic work-up always comes before any treatment decision — immunotherapy is not a one-size-fits-all option.

Who qualifies for immunotherapy? Eligibility depends on cancer type, stage, and biomarker results such as PD-L1 expression or genetic mutations. Doctors also review a patient’s overall health and immune status. A multidisciplinary oncology team confirms candidacy through diagnostic testing before starting treatment.

Benefits of Immunotherapy

✔ Can produce long-lasting responses in some patients, even after treatment ends

✔ Often more targeted than traditional chemotherapy, which may reduce certain side effects

✔ Available as a single treatment or combined with chemotherapy, radiation, or surgery

✔ Growing number of approved uses across multiple cancer types

✔ Some patients experience improved quality of life during treatment compared to intensive chemotherapy regimens

✔ Ongoing research continues to expand safe and effective uses

It’s important to know that responses vary widely between patients. Immunotherapy helps many people, but it does not work for everyone, and outcomes cannot be guaranteed.

Risks and Side Effects of Immunotherapy

Immunotherapy is generally well-tolerated, but because it activates the immune system, it can sometimes cause the immune system to attack healthy tissue as well as cancer cells. Most side effects are manageable when caught early.

Common Side Effects

• Fatigue
• Skin rash or itching
• Flu-like symptoms (fever, chills)
• Nausea
• Diarrhea
• Joint or muscle pain

Immune-Related Adverse Effects

Less commonly, immunotherapy can cause inflammation in organs such as the lungs, liver, intestines, kidneys, thyroid, or other hormone-producing glands. CAR T-cell therapy carries specific risks, including cytokine release syndrome (a systemic inflammatory reaction) and temporary neurological effects, both of which require close hospital-based monitoring, especially in the days following infusion.

These effects are taken seriously, but they are typically identified early and managed effectively by an experienced oncology team using established monitoring protocols and, when needed, medications that calm the immune response. Patients are monitored closely throughout treatment through regular blood work, imaging, and clinical check-ins, and are encouraged to report new symptoms immediately rather than waiting for a scheduled visit.

Immunotherapy vs Chemotherapy: A Detailed Comparison

Is immunotherapy better than chemotherapy?

Neither is universally “better.” Immunotherapy targets the immune system and works well for cancers with specific biomarkers, often with different side effects than chemotherapy. Chemotherapy remains essential for many cancers. The right choice depends on cancer type, stage, and individual patient factors.

The Immunotherapy Treatment Process

Step 1 — Consultation: Patients meet with an oncology specialist to review medical history, previous treatments, and current health status.

Step 2 — Diagnosis and Testing: Biopsy, imaging, and laboratory tests confirm the cancer type, stage, and relevant biomarkers such as PD-L1 or genetic mutations.

Step 3 — Eligibility Review: A multidisciplinary tumor board reviews test results to determine whether immunotherapy is appropriate, alone or combined with other treatments.

Step 4 — Treatment: Depending on the type, immunotherapy is given by IV infusion, injection, or, for CAR T-cell therapy, a one-time cell infusion after a preparatory regimen.

Step 5 — Monitoring: Regular blood tests, imaging scans, and clinical evaluations track response and watch for side effects throughout treatment.

Step 6 — Follow-Up: After the treatment course, patients continue periodic scans and check-ins to monitor long-term response and overall health.

How long does immunotherapy take?

Treatment length varies by type and cancer. Checkpoint inhibitors are often given every two to six weeks for months or longer. CAR T-cell therapy involves a single infusion after several weeks of preparation, followed by close monitoring for the first month.

Is immunotherapy painful?

Most immunotherapy infusions are similar to an IV drip and are not painful, though some patients feel discomfort at the injection site or mild flu-like symptoms afterward. CAR T-cell therapy involves a more intensive process requiring hospital monitoring.

Why Choose Viezec Healthcare?

Viezec supports international patients and families in navigating cancer care with clarity and coordination. Our role is to help you connect with experienced oncology specialists and accredited hospitals, and to guide you through what can otherwise be an overwhelming process.

• Medical coordination: We help organize consultations, second opinions, and diagnostic reviews with oncology specialists so your treatment plan is based on your specific case.
• Experienced specialist network: We work with oncologists and hospital teams experienced in immunotherapy protocols, including checkpoint inhibitor therapy and CAR T-cell programs where available.
• Support for international patients: From documentation to language assistance, our team helps international and medical tourist patients move through the process smoothly.
• Treatment planning: We help coordinate diagnostic work-up, cost estimates, and scheduling with the treating hospital before you travel.
• Travel assistance: Support with logistics such as accommodation guidance and appointment scheduling around your treatment timeline.
• Follow-up coordination: We help facilitate continued communication with your treating specialists after the initial treatment phase.

Viezec does not provide treatment directly — we coordinate access to qualified specialists and hospitals so that patients can make informed, well-supported decisions. We do not promise cures, and any treatment plan is determined solely by the treating oncology team based on your individual diagnosis.

Learn more about our international patient services or explore our medical team’s credentials.

Ready to explore your options? Book a consultation with our medical coordination team to discuss whether immunotherapy may be relevant to your case, and to get connected with an experienced oncology specialist.

Frequently Asked Questions

1. What is immunotherapy in simple terms?

Immunotherapy is a cancer treatment that helps your own immune system recognize and fight cancer cells. Instead of directly attacking the tumor like chemotherapy or radiation, it removes the “brakes” cancer cells use to hide from immune cells, or it re-engineers immune cells to target cancer directly. It is used for specific cancer types and stages, decided after testing confirms it is likely to help.

2. How is immunotherapy different from chemotherapy?

Chemotherapy directly kills fast-dividing cells, including some healthy ones, which is why it causes side effects like hair loss. Immunotherapy instead activates the immune system to identify and destroy cancer cells, often with a different side-effect profile. Some patients receive both, depending on their cancer type, stage, and biomarker results, as determined by their oncology team.

3. Who is a good candidate for immunotherapy?

Candidacy depends on cancer type, stage, biomarker results such as PD-L1 expression, and overall health. Certain cancers, like melanoma, lung cancer, and some blood cancers, respond well in eligible patients. A multidisciplinary oncology team reviews diagnostic tests before confirming whether immunotherapy is appropriate for an individual case.

4. Is immunotherapy safe?

Immunotherapy is generally well-tolerated, but it can cause side effects because it stimulates the immune system. Most reactions are mild, such as fatigue or rash, but immune-related inflammation of organs can occur in some patients. Close monitoring by an oncology team helps catch and manage side effects early, making treatment safer overall.

5. What cancers can immunotherapy treat?

Immunotherapy is an established option for melanoma, non-small cell lung cancer, kidney cancer, bladder cancer, certain lymphomas and leukemias, head and neck cancers, and selected cases of liver, breast, and colorectal cancer. Use in other cancers may still be under clinical investigation, depending on the specific indication and country.

6. How long does immunotherapy treatment last?

Duration varies by therapy type and individual response. Checkpoint inhibitors are typically given every few weeks for several months or longer, sometimes as maintenance therapy. CAR T-cell therapy is usually a one-time infusion following a preparation period, with intensive monitoring in the following weeks.

7. What are the common side effects of immunotherapy?

Common side effects include fatigue, skin rash, flu-like symptoms, nausea, and joint pain. These are usually manageable. Less common but more serious immune-related side effects can affect organs like the lungs, liver, or thyroid, which is why regular monitoring throughout treatment is an essential part of care.

8. Can immunotherapy cure cancer?

Immunotherapy can lead to long-lasting remission in some patients, and ongoing research continues to improve outcomes, but it cannot be guaranteed to cure cancer in every case. Results vary based on cancer type, stage, and individual biology. Your oncology team can explain realistic expectations based on your specific diagnosis and test results.

9. How much does immunotherapy cost in India?

Costs vary significantly based on the type of immunotherapy, cancer type, treatment duration, and hospital. India is often considered by international patients due to comparatively lower treatment costs versus many Western countries, though exact pricing depends on individual diagnosis. Viezec can help provide cost estimates after reviewing your medical reports.

10. Is immunotherapy available in India?

Yes, immunotherapy, including checkpoint inhibitors and monoclonal antibody treatments, is available at leading cancer hospitals in India. Certain advanced options, like CAR T-cell therapy, may be available at select specialized centers. Availability depends on the specific therapy and cancer type, so it’s important to confirm with the treating hospital.

11. How is eligibility for immunotherapy determined?

Eligibility is determined through biopsy results, imaging, and biomarker testing such as PD-L1 expression or genetic mutation analysis. Doctors also review overall health, prior treatments, and any autoimmune conditions. A multidisciplinary tumor board typically reviews these results together before recommending immunotherapy as part of a treatment plan.

12. What happens during an immunotherapy infusion?

Most immunotherapy drugs are given through an IV infusion, similar to a chemotherapy session, usually lasting 30 minutes to a few hours. Patients are monitored during and after the infusion for any immediate reactions. Sessions are typically scheduled every two to six weeks, depending on the specific drug protocol.

13. Can immunotherapy be combined with other treatments?

Yes. Immunotherapy is often combined with chemotherapy, radiation, targeted therapy, or surgery, depending on the cancer type and stage. Combination approaches are decided by the oncology team based on clinical evidence for the specific cancer, aiming to improve overall treatment effectiveness while managing side effects.

14. What is the difference between CAR T-cell therapy and checkpoint inhibitors?

Checkpoint inhibitors are drugs that block proteins cancer cells use to suppress immune attack, allowing existing T cells to work better. CAR T-cell therapy is a personalized process where a patient’s own T cells are removed, genetically modified to target cancer, multiplied, and reinfused. Both are immunotherapy but work through different mechanisms.

15. How do I know if immunotherapy is right for me or my family member?

The only way to know is through a proper diagnostic work-up and consultation with an oncology specialist, including biomarker and genetic testing specific to your cancer type. Viezec can help coordinate this evaluation with experienced specialists so you receive a personalized, evidence-based recommendation rather than a generic answer.